Apatinib in metastatic gastric cancer: can paclitaxel make the difference?
aDepartment of Molecular and Translational Medicine, University of Brescia, Brescia bUnit of Molecular Therapy and Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Viale Concordia, Cremona cUnit of General and Minimally Invasive Surgery, Surgery and Neuroscience; University of Siena, Viale Bracci, Siena dDepartment of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale, Trieste, Italy.
Giandomenico
G
Roviello
Franco
F
Roviello
Karol
K
Polom
Daniele
D
Generali
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy*; D000096662:Ramucirumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D017239:Paclitaxel; D011725:Pyridines; D000096662:Ramucirumab; C553458:apatinib